ID   SC6A8_HUMAN             Reviewed;         635 AA.
AC   P48029; B2KY47; B4DIA3; E9PFC0; Q13032; Q66I36;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 1.
DT   10-MAY-2017, entry version 163.
DE   RecName: Full=Sodium- and chloride-dependent creatine transporter 1;
DE            Short=CT1;
DE            Short=Creatine transporter 1;
DE   AltName: Full=Solute carrier family 6 member 8;
GN   Name=SLC6A8;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Kidney;
RX   PubMed=7953292;
RA   Nash S.R., Giros B., Kingsmore S.F., Rochelle J.M., Suter S.T.,
RA   Gregor P., Seldin M.F., Caron M.G.;
RT   "Cloning, pharmacological characterization, and genomic localization
RT   of the human creatine transporter.";
RL   Recept. Channels 2:165-174(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=7945388; DOI=10.1006/bbrc.1994.2475;
RA   Sora I., Richman J., Santoro G., Wei H., Wang Y., Vanderah T.,
RA   Horvath R., Nguyen M., Waite S., Roeske W.R.;
RT   "The cloning and expression of a human creatine transporter.";
RL   Biochem. Biophys. Res. Commun. 204:419-427(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8661155; DOI=10.1006/geno.1996.0373;
RA   Sandoval N., Bauer D., Brenner V., Coy J.F., Drescher B., Kioschis P.,
RA   Korn B., Nyakatura G., Poustka A., Reichwald K., Rosenthal A.,
RA   Platzer M.;
RT   "The genomic organization of a human creatine transporter (CRTR) gene
RT   located in Xq28.";
RL   Genomics 35:383-385(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Hippocampus;
RX   PubMed=7622069; DOI=10.1016/0378-1119(95)00104-E;
RA   Barnwell L.F., Chaudhuri G., Townsel J.G.;
RT   "Cloning and sequencing of a cDNA encoding a novel member of the human
RT   brain GABA/noradrenaline neurotransmitter transporter family.";
RL   Gene 159:287-288(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RX   PubMed=18515020; DOI=10.1016/j.gene.2008.04.003;
RA   Martinez-Munoz C., Rosenberg E.H., Jakobs C., Salomons G.S.;
RT   "Identification, characterization and cloning of SLC6A8C, a novel
RT   splice variant of the creatine transporter gene.";
RL   Gene 418:53-59(2008).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Eichler E.E., Lu F., Shen Y., Muzny D.M., Gibbs R.A., Nelson D.L.;
RT   "Genomic organization of the human creatine transporter and CDM
RT   genes.";
RL   Submitted (SEP-1995) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Eye, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-42, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-42; THR-617 AND THR-620,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   VARIANT CCDS1 ARG-381.
RX   PubMed=11898126; DOI=10.1086/340092;
RA   Hahn K.A., Salomons G.S., Tackels-Horne D., Wood T.C., Taylor H.A.,
RA   Schroer R.J., Lubs H.A., Jakobs C., Olson R.L., Holden K.R.,
RA   Stevenson R.E., Schwartz C.E.;
RT   "X-linked mental retardation with seizures and carrier manifestations
RT   is caused by a mutation in the creatine-transporter gene (SLC6A8)
RT   located in Xq28.";
RL   Am. J. Hum. Genet. 70:1349-1356(2002).
RN   [14]
RP   VARIANT CCDS1 PHE-408 DEL.
RX   PubMed=12210795; DOI=10.1002/ana.10246;
RA   Bizzi A., Bugiani M., Salomons G.S., Hunneman D.H., Moroni I.,
RA   Estienne M., Danesi U., Jakobs C., Uziel G.;
RT   "X-linked creatine deficiency syndrome: a novel mutation in creatine
RT   transporter gene SLC6A8.";
RL   Ann. Neurol. 52:227-231(2002).
RN   [15]
RP   VARIANTS CCDS1 ARG-87; TRP-337; LEU-390 AND LEU-554, AND VARIANT
RP   VAL-560.
RX   PubMed=15154114; DOI=10.1086/422102;
RA   Rosenberg E.H., Almeida L.S., Kleefstra T., deGrauw R.S., Yntema H.G.,
RA   Bahi N., Moraine C., Ropers H.-H., Fryns J.-P., deGrauw T.J.,
RA   Jakobs C., Salomons G.S.;
RT   "High prevalence of SLC6A8 deficiency in X-linked mental
RT   retardation.";
RL   Am. J. Hum. Genet. 75:97-105(2004).
RN   [16]
RP   VARIANTS CCDS1 VAL-132 AND TRP-491.
RX   PubMed=17101918; DOI=10.1212/01.wnl.0000239153.39710.81;
RA   Lion-Francois L., Cheillan D., Pitelet G., Acquaviva-Bourdain C.,
RA   Bussy G., Cotton F., Guibaud L., Gerard D., Rivier C.,
RA   Vianey-Saban C., Jakobs C., Salomons G.S., des Portes V.;
RT   "High frequency of creatine deficiency syndromes in patients with
RT   unexplained mental retardation.";
RL   Neurology 67:1713-1714(2006).
RN   [17]
RP   VARIANTS CCDS1 ARG-87; PHE-107 DEL; ASN-336 DEL; TRP-337; ILE-347 DEL;
RP   LEU-390; TRP-391 AND LEU-554, VARIANTS ARG-4; ARG-26; VAL-560 AND
RP   ILE-629, CHARACTERIZATION OF VARIANTS CCDS1 ARG-87; PHE-107 DEL;
RP   ASN-336 DEL; TRP-337; ILE-347 DEL; LEU-390 AND TRP-391, AND
RP   CHARACTERIZATION OF VARIANTS ARG-4; ARG-26; VAL-560 AND ILE-629.
RX   PubMed=17465020; DOI=10.1002/humu.20532;
RA   Rosenberg E.H., Martinez Munoz C., Betsalel O.T., van Dooren S.J.,
RA   Fernandez M., Jakobs C., deGrauw T.J., Kleefstra T., Schwartz C.E.,
RA   Salomons G.S.;
RT   "Functional characterization of missense variants in the creatine
RT   transporter gene (SLC6A8): improved diagnostic application.";
RL   Hum. Mutat. 28:890-896(2007).
RN   [18]
RP   VARIANT SER-550.
RX   PubMed=23092983; DOI=10.1038/tp.2012.102;
RA   Nava C., Lamari F., Heron D., Mignot C., Rastetter A., Keren B.,
RA   Cohen D., Faudet A., Bouteiller D., Gilleron M., Jacquette A.,
RA   Whalen S., Afenjar A., Perisse D., Laurent C., Dupuits C., Gautier C.,
RA   Gerard M., Huguet G., Caillet S., Leheup B., Leboyer M., Gillberg C.,
RA   Delorme R., Bourgeron T., Brice A., Depienne C.;
RT   "Analysis of the chromosome X exome in patients with autism spectrum
RT   disorders identified novel candidate genes, including TMLHE.";
RL   Transl. Psychiatry 2:E179-E179(2012).
RN   [19]
RP   VARIANT CCDS1 ASN-336 DEL.
RX   PubMed=24123876; DOI=10.1136/jmedgenet-2013-101644;
RA   Schuurs-Hoeijmakers J.H., Vulto-van Silfhout A.T., Vissers L.E.,
RA   van de Vondervoort I.I., van Bon B.W., de Ligt J., Gilissen C.,
RA   Hehir-Kwa J.Y., Neveling K., del Rosario M., Hira G., Reitano S.,
RA   Vitello A., Failla P., Greco D., Fichera M., Galesi O., Kleefstra T.,
RA   Greally M.T., Ockeloen C.W., Willemsen M.H., Bongers E.M.,
RA   Janssen I.M., Pfundt R., Veltman J.A., Romano C., Willemsen M.A.,
RA   van Bokhoven H., Brunner H.G., de Vries B.B., de Brouwer A.P.;
RT   "Identification of pathogenic gene variants in small families with
RT   intellectually disabled siblings by exome sequencing.";
RL   J. Med. Genet. 50:802-811(2013).
RN   [20]
RP   VARIANTS CCDS1 HIS-80; CYS-383; ASP-448 AND ILE-539.
RX   PubMed=23660394; DOI=10.1016/j.ymgme.2013.04.006;
RA   Comeaux M.S., Wang J., Wang G., Kleppe S., Zhang V.W., Schmitt E.S.,
RA   Craigen W.J., Renaud D., Sun Q., Wong L.J.;
RT   "Biochemical, molecular, and clinical diagnoses of patients with
RT   cerebral creatine deficiency syndromes.";
RL   Mol. Genet. Metab. 109:260-268(2013).
RN   [21]
RP   VARIANT CCDS1 LEU-552, CHARACTERIZATION OF VARIANT CCDS1 LEU-552,
RP   VARIANTS HIS-186; MET-270; GLN-294; LEU-314; THR-318; SER-550;
RP   LEU-564; THR-611 AND LYS-624, AND CHARACTERIZATION OF VARIANTS
RP   HIS-186; MET-270; GLN-294; LEU-314; THR-318; LEU-564; THR-611 AND
RP   LYS-624.
RX   PubMed=25861866; DOI=10.1016/j.gene.2015.04.011;
RA   DesRoches C.L., Patel J., Wang P., Minassian B., Salomons G.S.,
RA   Marshall C.R., Mercimek-Mahmutoglu S.;
RT   "Estimated carrier frequency of creatine transporter deficiency in
RT   females in the general population using functional characterization of
RT   novel missense variants in the SLC6A8 gene.";
RL   Gene 565:187-191(2015).
CC   -!- FUNCTION: Required for the uptake of creatine in muscles and
CC       brain.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=CRT1;
CC         IsoId=P48029-1; Sequence=Displayed;
CC       Name=2; Synonyms=CRT2, SLC6A8B;
CC         IsoId=P48029-2; Sequence=VSP_043917, VSP_043918, VSP_043919,
CC                                  VSP_043920;
CC       Name=3; Synonyms=SLC6A8C;
CC         IsoId=P48029-3; Sequence=VSP_043916;
CC       Name=4;
CC         IsoId=P48029-4; Sequence=VSP_046316;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in skeletal muscle and
CC       kidney. Also found in brain, heart, colon, testis and prostate.
CC       {ECO:0000269|PubMed:7945388, ECO:0000269|PubMed:7953292}.
CC   -!- DISEASE: Cerebral creatine deficiency syndrome 1 (CCDS1)
CC       [MIM:300352]: An X-linked disorder of creatine transport
CC       characterized by mental retardation, severe speech delay,
CC       behavioral abnormalities, and seizures. Carrier females may show
CC       mild neuropsychologic impairment. {ECO:0000269|PubMed:11898126,
CC       ECO:0000269|PubMed:12210795, ECO:0000269|PubMed:15154114,
CC       ECO:0000269|PubMed:17101918, ECO:0000269|PubMed:17465020,
CC       ECO:0000269|PubMed:23660394, ECO:0000269|PubMed:24123876,
CC       ECO:0000269|PubMed:25861866}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the sodium:neurotransmitter symporter (SNF)
CC       (TC 2.A.22) family. SLC6A8 subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L31409; AAC41688.1; -; mRNA.
DR   EMBL; S74039; AAB32284.1; -; mRNA.
DR   EMBL; U17986; AAA86990.1; -; mRNA.
DR   EMBL; EU280316; ABZ82022.1; -; mRNA.
DR   EMBL; AK295495; BAG58415.1; -; mRNA.
DR   EMBL; U52111; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z66539; CAA91442.1; -; Genomic_DNA.
DR   EMBL; U36341; AAA79507.1; -; Genomic_DNA.
DR   EMBL; BC012355; AAH12355.1; -; mRNA.
DR   EMBL; BC081558; AAH81558.1; -; mRNA.
DR   CCDS; CCDS14726.1; -. [P48029-1]
DR   CCDS; CCDS48190.1; -. [P48029-4]
DR   PIR; G02095; G02095.
DR   PIR; JC2386; JC2386.
DR   RefSeq; NP_001136277.1; NM_001142805.1.
DR   RefSeq; NP_001136278.1; NM_001142806.1. [P48029-4]
DR   RefSeq; NP_005620.1; NM_005629.3. [P48029-1]
DR   UniGene; Hs.540696; -.
DR   ProteinModelPortal; P48029; -.
DR   BioGrid; 112426; 10.
DR   IntAct; P48029; 4.
DR   STRING; 9606.ENSP00000253122; -.
DR   DrugBank; DB00148; Creatine.
DR   TCDB; 2.A.22.3.11; the neurotransmitter:sodium symporter (nss) family.
DR   iPTMnet; P48029; -.
DR   PhosphoSitePlus; P48029; -.
DR   SwissPalm; P48029; -.
DR   BioMuta; SLC6A8; -.
DR   DMDM; 1352529; -.
DR   EPD; P48029; -.
DR   PaxDb; P48029; -.
DR   PeptideAtlas; P48029; -.
DR   PRIDE; P48029; -.
DR   DNASU; 6535; -.
DR   Ensembl; ENST00000253122; ENSP00000253122; ENSG00000130821. [P48029-1]
DR   Ensembl; ENST00000430077; ENSP00000403041; ENSG00000130821. [P48029-4]
DR   GeneID; 6535; -.
DR   KEGG; hsa:6535; -.
DR   UCSC; uc011myx.2; human. [P48029-1]
DR   CTD; 6535; -.
DR   DisGeNET; 6535; -.
DR   GeneCards; SLC6A8; -.
DR   GeneReviews; SLC6A8; -.
DR   H-InvDB; HIX0038627; -.
DR   HGNC; HGNC:11055; SLC6A8.
DR   MalaCards; SLC6A8; -.
DR   MIM; 300036; gene.
DR   MIM; 300352; phenotype.
DR   neXtProt; NX_P48029; -.
DR   OpenTargets; ENSG00000130821; -.
DR   Orphanet; 52503; X-linked creatine transporter deficiency.
DR   PharmGKB; PA35915; -.
DR   eggNOG; KOG3659; Eukaryota.
DR   eggNOG; COG0733; LUCA.
DR   GeneTree; ENSGT00760000119044; -.
DR   HOGENOM; HOG000203877; -.
DR   HOVERGEN; HBG071421; -.
DR   InParanoid; P48029; -.
DR   KO; K05039; -.
DR   OMA; VPPRETW; -.
DR   OrthoDB; EOG091G08PX; -.
DR   PhylomeDB; P48029; -.
DR   TreeFam; TF343812; -.
DR   Reactome; R-HSA-71288; Creatine metabolism.
DR   GeneWiki; SLC6A8; -.
DR   GenomeRNAi; 6535; -.
DR   PRO; PR:P48029; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000130821; -.
DR   CleanEx; HS_SLC6A8; -.
DR   ExpressionAtlas; P48029; baseline and differential.
DR   Genevisible; P48029; HS.
DR   GO; GO:0016021; C:integral component of membrane; TAS:ProtInc.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005308; F:creatine transmembrane transporter activity; NAS:UniProtKB.
DR   GO; GO:0005309; F:creatine:sodium symporter activity; IBA:GO_Central.
DR   GO; GO:0005328; F:neurotransmitter:sodium symporter activity; IEA:InterPro.
DR   GO; GO:0006600; P:creatine metabolic process; TAS:Reactome.
DR   GO; GO:0015881; P:creatine transport; IMP:UniProtKB.
DR   GO; GO:0006936; P:muscle contraction; TAS:ProtInc.
DR   GO; GO:0006810; P:transport; TAS:ProtInc.
DR   InterPro; IPR000175; Na/ntran_symport.
DR   InterPro; IPR002984; Na/ntran_symport_creatine.
DR   PANTHER; PTHR11616; PTHR11616; 1.
DR   Pfam; PF00209; SNF; 1.
DR   PRINTS; PR01199; CRTTRANSPORT.
DR   PRINTS; PR00176; NANEUSMPORT.
DR   PROSITE; PS00610; NA_NEUROTRAN_SYMP_1; 1.
DR   PROSITE; PS00754; NA_NEUROTRAN_SYMP_2; 1.
DR   PROSITE; PS50267; NA_NEUROTRAN_SYMP_3; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; Disease mutation;
KW   Glycoprotein; Ion transport; Membrane; Mental retardation;
KW   Phosphoprotein; Polymorphism; Reference proteome; Sodium;
KW   Sodium transport; Symport; Transmembrane; Transmembrane helix;
KW   Transport.
FT   CHAIN         1    635       Sodium- and chloride-dependent creatine
FT                                transporter 1.
FT                                /FTId=PRO_0000214774.
FT   TOPO_DOM      1     60       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     61     81       Helical. {ECO:0000255}.
FT   TOPO_DOM     82     87       Extracellular. {ECO:0000255}.
FT   TRANSMEM     88    108       Helical. {ECO:0000255}.
FT   TOPO_DOM    109    138       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    139    159       Helical. {ECO:0000255}.
FT   TOPO_DOM    160    230       Extracellular. {ECO:0000255}.
FT   TRANSMEM    231    251       Helical. {ECO:0000255}.
FT   TOPO_DOM    252    269       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    270    290       Helical. {ECO:0000255}.
FT   TOPO_DOM    291    304       Extracellular. {ECO:0000255}.
FT   TRANSMEM    305    325       Helical. {ECO:0000255}.
FT   TOPO_DOM    326    341       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    342    362       Helical. {ECO:0000255}.
FT   TOPO_DOM    363    394       Extracellular. {ECO:0000255}.
FT   TRANSMEM    395    415       Helical. {ECO:0000255}.
FT   TOPO_DOM    416    444       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    445    465       Helical. {ECO:0000255}.
FT   TOPO_DOM    466    479       Extracellular. {ECO:0000255}.
FT   TRANSMEM    480    500       Helical. {ECO:0000255}.
FT   TOPO_DOM    501    520       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    521    541       Helical. {ECO:0000255}.
FT   TOPO_DOM    542    560       Extracellular. {ECO:0000255}.
FT   TRANSMEM    561    581       Helical. {ECO:0000255}.
FT   TOPO_DOM    582    635       Cytoplasmic. {ECO:0000255}.
FT   MOD_RES      42     42       Phosphothreonine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     617    617       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     620    620       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     623    623       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8VBW1}.
FT   CARBOHYD    192    192       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    197    197       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    548    548       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ       1    365       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:18515020}.
FT                                /FTId=VSP_043916.
FT   VAR_SEQ       1    259       MAKKSAENGIYSVSGDEKKGPLIAPGPDGAPAKGDGPVGLG
FT                                TPGGRLAVPPRETWTRQMDFIMSCVGFAVGLGNVWRFPYLC
FT                                YKNGGGVFLIPYVLIALVGGIPIFFLEISLGQFMKAGSINV
FT                                WNICPLFKGLGYASMVIVFYCNTYYIMVLAWGFYYLVKSFT
FT                                TTLPWATCGHTWNTPDCVEIFRHEDCANASLANLTCDQLAD
FT                                RRSPVIEFWENKVLRLSGGLEVPGALNWEVTLCLLACWVLV
FT                                YFCVWKGVKSTGK -> MLPTLQIQGPAAFAPGDRGPGRHC
FT                                PFPVPITPTGALLPVSDSCDSLVDLVWPSVTYLALGTQSRV
FT                                WPHPLGAPGQAGESPEQRRQCLELWDMASSLGDKVPRAACG
FT                                KRGQTVWQLHLACLCLAQFHSPPAQPPPLSRRGGGPDPDPI
FT                                SRSLPGPPTPALPTHSYSSHSPRAPRLLSPLRRAPRGSPAP
FT                                HRHASLQTNEAPRELPHCTWPGLPGRSLAPSFLWREPWLGG
FT                                QWGPLNIPARKGDRRRWEWGCEGGGATASAEQPGPQ (in
FT                                isoform 2). {ECO:0000303|PubMed:7622069}.
FT                                /FTId=VSP_043917.
FT   VAR_SEQ       1    115       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_046316.
FT   VAR_SEQ     417    417       S -> SQVCMGLWDREPGGGRREGCRQGKGWRRCGDRPELP
FT                                WP (in isoform 2).
FT                                {ECO:0000303|PubMed:7622069}.
FT                                /FTId=VSP_043918.
FT   VAR_SEQ     464    464       D -> DVSGVGGLPVTSGGRLPSSLTGLCPQ (in
FT                                isoform 2). {ECO:0000303|PubMed:7622069}.
FT                                /FTId=VSP_043919.
FT   VAR_SEQ     498    498       Y -> YGRSWLRAGLGDGGGEGRSPAWPSRLTSPQ (in
FT                                isoform 2). {ECO:0000303|PubMed:7622069}.
FT                                /FTId=VSP_043920.
FT   VARIANT       4      4       K -> R (polymorphism; no effect on
FT                                creatine transporter activity).
FT                                {ECO:0000269|PubMed:17465020}.
FT                                /FTId=VAR_075562.
FT   VARIANT      26     26       G -> R (polymorphism; no effect on
FT                                creatine transporter activity).
FT                                {ECO:0000269|PubMed:17465020}.
FT                                /FTId=VAR_075563.
FT   VARIANT      80     80       Y -> H (in CCDS1).
FT                                {ECO:0000269|PubMed:23660394}.
FT                                /FTId=VAR_071791.
FT   VARIANT      87     87       G -> R (in CCDS1; decreased creatine
FT                                transporter activity; dbSNP:rs122453115).
FT                                {ECO:0000269|PubMed:15154114,
FT                                ECO:0000269|PubMed:17465020}.
FT                                /FTId=VAR_020525.
FT   VARIANT     107    107       Missing (in CCDS1; decreased creatine
FT                                transporter activity).
FT                                {ECO:0000269|PubMed:17465020}.
FT                                /FTId=VAR_075564.
FT   VARIANT     132    132       G -> V (in CCDS1; dbSNP:rs122453117).
FT                                {ECO:0000269|PubMed:17101918}.
FT                                /FTId=VAR_063707.
FT   VARIANT     164    164       T -> S (in dbSNP:rs642454).
FT                                /FTId=VAR_034483.
FT   VARIANT     186    186       R -> H (polymorphism; 82.0% of wild type
FT                                creatine transporter activity;
FT                                dbSNP:rs372601430).
FT                                {ECO:0000269|PubMed:25861866}.
FT                                /FTId=VAR_074262.
FT   VARIANT     270    270       V -> M (polymorphism; no effect on
FT                                creatine transporter activity;
FT                                dbSNP:rs146985734).
FT                                {ECO:0000269|PubMed:25861866}.
FT                                /FTId=VAR_074263.
FT   VARIANT     294    294       K -> Q (polymorphism; no effect on
FT                                creatine transporter activity;
FT                                dbSNP:rs376937460).
FT                                {ECO:0000269|PubMed:25861866}.
FT                                /FTId=VAR_074264.
FT   VARIANT     314    314       F -> L (polymorphism; 65.0% of wild type
FT                                creatine transporter activity;
FT                                dbSNP:rs144678921).
FT                                {ECO:0000269|PubMed:25861866}.
FT                                /FTId=VAR_074265.
FT   VARIANT     318    318       A -> T (polymorphism; 78.0% of wild type
FT                                creatine transporter activity;
FT                                dbSNP:rs373953317).
FT                                {ECO:0000269|PubMed:25861866}.
FT                                /FTId=VAR_074266.
FT   VARIANT     336    336       Missing (in CCDS1; decreased creatine
FT                                transporter activity).
FT                                {ECO:0000269|PubMed:17465020,
FT                                ECO:0000269|PubMed:24123876}.
FT                                /FTId=VAR_070563.
FT   VARIANT     337    337       C -> W (in CCDS1; decreased creatine
FT                                transporter activity; dbSNP:rs122453116).
FT                                {ECO:0000269|PubMed:15154114,
FT                                ECO:0000269|PubMed:17465020}.
FT                                /FTId=VAR_063708.
FT   VARIANT     347    347       Missing (in CCDS1; decreased creatine
FT                                transporter activity).
FT                                {ECO:0000269|PubMed:17465020}.
FT                                /FTId=VAR_075565.
FT   VARIANT     381    381       G -> R (in CCDS1; dbSNP:rs122453114).
FT                                {ECO:0000269|PubMed:11898126}.
FT                                /FTId=VAR_020526.
FT   VARIANT     383    383       G -> C (in CCDS1).
FT                                {ECO:0000269|PubMed:23660394}.
FT                                /FTId=VAR_071792.
FT   VARIANT     390    390       P -> L (in CCDS1; decreased creatine
FT                                transporter activity).
FT                                {ECO:0000269|PubMed:15154114,
FT                                ECO:0000269|PubMed:17465020}.
FT                                /FTId=VAR_020527.
FT   VARIANT     391    391       R -> W (in CCDS1; decreased creatine
FT                                transporter activity).
FT                                {ECO:0000269|PubMed:17465020}.
FT                                /FTId=VAR_075566.
FT   VARIANT     408    408       Missing (in CCDS1).
FT                                {ECO:0000269|PubMed:12210795}.
FT                                /FTId=VAR_020528.
FT   VARIANT     448    448       A -> D (in CCDS1).
FT                                {ECO:0000269|PubMed:23660394}.
FT                                /FTId=VAR_071793.
FT   VARIANT     491    491       C -> W (in CCDS1; dbSNP:rs122453118).
FT                                {ECO:0000269|PubMed:17101918}.
FT                                /FTId=VAR_063709.
FT   VARIANT     539    539       V -> I (in CCDS1; dbSNP:rs782354054).
FT                                {ECO:0000269|PubMed:23660394}.
FT                                /FTId=VAR_071794.
FT   VARIANT     550    550       T -> S (in dbSNP:rs199635059).
FT                                {ECO:0000269|PubMed:23092983,
FT                                ECO:0000269|PubMed:25861866}.
FT                                /FTId=VAR_074267.
FT   VARIANT     552    552       V -> L (in CCDS1; unknown pathological
FT                                significance; 35.0% of wild type creatine
FT                                transporter activity; dbSNP:rs372567920).
FT                                {ECO:0000269|PubMed:25861866}.
FT                                /FTId=VAR_074268.
FT   VARIANT     554    554       P -> L (in CCDS1; decreased creatine
FT                                transporter activity; dbSNP:rs397515559).
FT                                {ECO:0000269|PubMed:15154114,
FT                                ECO:0000269|PubMed:17465020}.
FT                                /FTId=VAR_020529.
FT   VARIANT     560    560       M -> V (polymorphism; no effect on
FT                                creatine transporter activity;
FT                                dbSNP:rs145438966).
FT                                {ECO:0000269|PubMed:15154114,
FT                                ECO:0000269|PubMed:17465020}.
FT                                /FTId=VAR_063710.
FT   VARIANT     564    564       F -> L (polymorphism; no effect on
FT                                creatine transporter activity;
FT                                dbSNP:rs201044530).
FT                                {ECO:0000269|PubMed:25861866}.
FT                                /FTId=VAR_074269.
FT   VARIANT     611    611       A -> T (polymorphism; no effect on
FT                                creatine transporter activity;
FT                                dbSNP:rs146949376).
FT                                {ECO:0000269|PubMed:25861866}.
FT                                /FTId=VAR_074270.
FT   VARIANT     624    624       E -> K (polymorphism; no effect on
FT                                creatine transporter activity;
FT                                dbSNP:rs368555229).
FT                                {ECO:0000269|PubMed:25861866}.
FT                                /FTId=VAR_074271.
FT   VARIANT     629    629       V -> I (polymorphism; no effect on
FT                                creatine transporter activity;
FT                                dbSNP:rs781899045).
FT                                {ECO:0000269|PubMed:17465020}.
FT                                /FTId=VAR_075567.
FT   CONFLICT     24     25       AP -> VS (in Ref. 2; AAB32284).
FT                                {ECO:0000305}.
FT   CONFLICT     32     32       A -> S (in Ref. 2; AAB32284).
FT                                {ECO:0000305}.
FT   CONFLICT     38     38       V -> A (in Ref. 2; AAB32284).
FT                                {ECO:0000305}.
FT   CONFLICT     42     45       TPGG -> APSS (in Ref. 2; AAB32284).
FT                                {ECO:0000305}.
FT   CONFLICT    136    136       A -> G (in Ref. 7; BAG58415).
FT                                {ECO:0000305}.
FT   CONFLICT    193    193       A -> D (in Ref. 2; AAB32284).
FT                                {ECO:0000305}.
FT   CONFLICT    223    223       G -> T (in Ref. 2; AAB32284).
FT                                {ECO:0000305}.
FT   CONFLICT    285    285       A -> P (in Ref. 1; AAC41688).
FT                                {ECO:0000305}.
FT   CONFLICT    368    368       A -> T (in Ref. 2; AAB32284).
FT                                {ECO:0000305}.
FT   CONFLICT    434    434       P -> R (in Ref. 9; AAH81558).
FT                                {ECO:0000305}.
SQ   SEQUENCE   635 AA;  70523 MW;  9FAFE100B2A5B845 CRC64;
     MAKKSAENGI YSVSGDEKKG PLIAPGPDGA PAKGDGPVGL GTPGGRLAVP PRETWTRQMD
     FIMSCVGFAV GLGNVWRFPY LCYKNGGGVF LIPYVLIALV GGIPIFFLEI SLGQFMKAGS
     INVWNICPLF KGLGYASMVI VFYCNTYYIM VLAWGFYYLV KSFTTTLPWA TCGHTWNTPD
     CVEIFRHEDC ANASLANLTC DQLADRRSPV IEFWENKVLR LSGGLEVPGA LNWEVTLCLL
     ACWVLVYFCV WKGVKSTGKI VYFTATFPYV VLVVLLVRGV LLPGALDGII YYLKPDWSKL
     GSPQVWIDAG TQIFFSYAIG LGALTALGSY NRFNNNCYKD AIILALINSG TSFFAGFVVF
     SILGFMAAEQ GVHISKVAES GPGLAFIAYP RAVTLMPVAP LWAALFFFML LLLGLDSQFV
     GVEGFITGLL DLLPASYYFR FQREISVALC CALCFVIDLS MVTDGGMYVF QLFDYYSASG
     TTLLWQAFWE CVVVAWVYGA DRFMDDIACM IGYRPCPWMK WCWSFFTPLV CMGIFIFNVV
     YYEPLVYNNT YVYPWWGEAM GWAFALSSML CVPLHLLGCL LRAKGTMAER WQHLTQPIWG
     LHHLEYRAQD ADVRGLTTLT PVSESSKVVV VESVM
//
